Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD | MicrobiomeTrials← Back to trialsNCT05468073
Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-10-11Est. Completion: 2028-06-08
Enrollment target: 40 participants Locations- GHU Saint Anne, Paris, France
Other microbiome trials you might be interested in
LeukemiaLymphomaMultiple MyelomaMyelodysplastic Syndromes (MDS)Myeloproliferative Neoplasm
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and…
Omaha, United StatesEst. completion Jul 2027
Genetic Predisposition to DiseaseHealthy VolunteerAPOE-4 Positive
Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaq…
Columbia, United States
Est. completion Dec 31, 2027
Alzheimers DiseaseDementiaAlzheimers Disease, Familial
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants…
Birmingham, United StatesEst. completion Mar 30, 2034